# Acid-base & chloride

<!--

## Renal control of acid-base balance  

net acid excretion = titratable acid + NH4+ - HCO3-

Robinson 1961 (and see also Hamm CJASN 2015 etc.):

If acid load on Western diet = 1 mmol/kg/day and urine pH 4 = 0.1 mM then without buffering would need 700L urine per day!  

Therefore to excrete an acid load:  

1) reabsorb filtered HCO3  
2) excrete titratable acid (H2PO4) = net HCO3 reabsorption  
3) excrete ammonium (glutamine > NH3 + H+ > NH4) = net HCO3 reabsorption  

Excretion of NH4 is upregulated in response to acid load.  (Titratable acid = fixed.)  

In book chapter:

- acid excreted as NH4+ to avoid v. low urine pH = urate precipitation (pK 5.3)  
- base excreted as citrate (and other organic anions) to avoid v. high urine pH = calcium phosphate precipitation (pK 6.8)  

-->

## Normal ranges

- pH: *7.35 -- 7.45*
- PaCO~2~: *4.6 -- 6.0 kPa; 1 kPa = 7.5 mmHg*
- HCO~3~: *22 -- 30 mM*
- BE: *± 2 mM*

\BeginKnitrBlock{eqnpanel}<div class="eqnpanel">\begin{equation}
  pH=-log[H^{+}]
  (\#eq:pH1)
\end{equation}

\begin{equation}
  H^{+} = 10^{pH}
  (\#eq:pH2)
\end{equation}
    </div>\EndKnitrBlock{eqnpanel}


## Adaptation

Metabolic adaptation to respiratory alkalosis:  

+  acute (5 -- 10 mins) HCO~3~ 16 -- 18 mM *buffering by serum HCO~3~* 
+  chronic (2 -- 3 days) HCO~3~ 12 -- 15 mM *renal excretion of HCO3* 

Respiratory adaptation:  

+  for each mM HCO~3~ \< 25 PaCO~2~ should drop by... 0.16 kPa (1.2 mmHg) 
+  for each mM HCO~3~ \> 25 PaCO~2~ should rise by... 0.08 kPa (0.6 mmHg) 
+  Winter's formula: PaCO2 (mmHg) = (1.5 × HCO~3~) + 8 +/- 2 *(in metabolic acidosis)*  


## Metabolic alkalosis (& chloride homeostasis)  

### Causes of a metabolic alkalosis  

The causes of a metabolic alkalosis can be classified as being either due to chloride depletion (and therefore `chloride responsive`) or due to other causes (`chloride resistant`) [@luke2012a].  

<!-- +  low ECF volume = chloride-depletion / contractional = chloride-responsive  -->
<!--     +  *vomiting / NG losses*  -->
<!--     +  *loop / thiazide diuretics \**  -->
<!--     +  *Bartter's / Gitelman's \**  -->
<!--     +  *colonic villous adenoma / congenital chloride diarrhoea / high-volume ileostomy (rare)*   -->

<!-- +  normal ECF volume = chloride-resistant  -->
<!--     +  renal H + loss  -->
<!--         +  *true mineralocorticoid XS (low-renin / high-renin)*  -->
<!--         +  *apparent mineralocorticoid XS (and Liddle's)*  -->
<!--         +  *Cushings*  -->
<!--         +  *post-hypercapnic alkalosis (UCl \< 10 mM)*  -->
<!--         +  *milk-alkali syndrome*   -->
<!--     +  intracellular H + shift  -->
<!--         +  *hypokalaemia*   -->

<table>
<tbody>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> LOW ECF VOLUME = CHLORIDE-DEPLETION / CHLORIDE-RESPONSIVE </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> GI chloride loss </td>
   <td style="text-align:left;"> vomiting / NG losses </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> LOW ECF VOLUME = CHLORIDE-DEPLETION / CHLORIDE-RESPONSIVE </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> GI chloride loss </td>
   <td style="text-align:left;"> colonic villous adenoma / congenital chloride diarrhoea / high-volume ileostomy (rare) </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> LOW ECF VOLUME = CHLORIDE-DEPLETION / CHLORIDE-RESPONSIVE </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> renal chloride loss </td>
   <td style="text-align:left;"> loop / thiazide diuretics * </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> LOW ECF VOLUME = CHLORIDE-DEPLETION / CHLORIDE-RESPONSIVE </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> renal chloride loss </td>
   <td style="text-align:left;"> Bartter / Gitelman * </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> NORMAL ECF VOLUME = CHLORIDE-RESISTANT </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> renal H + loss </td>
   <td style="text-align:left;"> true mineralocorticoid XS (low-renin / high-renin) </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> NORMAL ECF VOLUME = CHLORIDE-RESISTANT </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> renal H + loss </td>
   <td style="text-align:left;"> apparent mineralocorticoid XS (and Liddle’s) </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> NORMAL ECF VOLUME = CHLORIDE-RESISTANT </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> renal H + loss </td>
   <td style="text-align:left;"> Cushings </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> NORMAL ECF VOLUME = CHLORIDE-RESISTANT </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> renal H + loss </td>
   <td style="text-align:left;"> post-hypercapnic alkalosis (UCl &lt; 10 mM) </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> NORMAL ECF VOLUME = CHLORIDE-RESISTANT </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> renal H + loss </td>
   <td style="text-align:left;"> milk-alkali syndrome </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> NORMAL ECF VOLUME = CHLORIDE-RESISTANT </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> intracellular H + shift </td>
   <td style="text-align:left;"> hypokalaemia </td>
  </tr>
</tbody>
</table>

\* in chloride-responsive states UCl \< 10 mM except where chloride is being lost in the urine (i.e. diuretics / Gitelman / Barrter syndrome).

Post-hypercapnic alkalosis occurs if chronic hypercapnia suddenly corrected (e.g. by mechanical ventilation).

The milk-alkali syndrome is the triad of hypercalcaemia, metabolic alkalosis and ingestion of large quantities of calcium with alkali; hypercalcaemia increases renal bicarbonate reabsorption (exacerbating alkalosis).


### Chloride

U~Cl~ NR = 100 -- 250 mmol / 24 hrs

In chloride-responsive alkalosis, UCl \< 10 mM:  

- vomiting  
- villous adenoma  
- congenital chloride diarrhoea  
- recent diuretics (pause on clinic day in surruptitious use)

In chloride-resistant alkalosis UCl \> 10 -- 30 mM (and also if chloride loss is due to diuretics / tubulopathies).  

UCl is persistently low after vomiting and is therefore a useful test for surreptitious vomiting.


#### Chloride-depletion alkalosis

In chloride depletion, reduced ECF volume leads to reduced GFR (less filtered NaHCO~3~) and increased Na reabsorption. Thus NaHCO~3~ reabsorption is increased. Increased distal Na reabsorption leads to increased acid excretion.  Therefore, after [vomiting](#vomit), an acid urine is produced (paradoxically) in the face of a metabolic alkalosis. Treatment is volume expansion with NaCl and correction of hypoK.


## Metabolic acidosis

### Anion & osmolar gaps

Metabolic acidoses are classified as `wide-anion-gap` (WGMA) or `normal-anion-gap` (= hyperchloraemic, HCMA).  In WGMA, the acidosis is caused by an exogenous acid present in plasma.  This is not measured directly, but will manifest as an apparent "anion gap".  

\BeginKnitrBlock{eqnpanel}<div class="eqnpanel">\begin{equation}
  \text{anion gap, } AG=P_{Na}-P_{HCO_{3}}-P_{Cl}
  (\#eq:AGap)
\end{equation}

NB some people also include P~K~ in the calculation.  
    
\begin{equation}
  \text{corrected anion gap, } cAG=AG+\frac{40-P_{albumin}}{4}
  (\#eq:cAGap)
\end{equation}
    
NB ADD ON to correct for hypoalbuminaemia.  
    </div>\EndKnitrBlock{eqnpanel}

![](figures/cAG.png)

A normal AG is 12 ± 2 (or 16 ± 2 if include K^+^ in the calculation).  

'Deltas' are calculated by comparing to expected normal values (for AG or HCO~3~).  

\BeginKnitrBlock{eqnpanel}<div class="eqnpanel">\begin{equation}
  \text{delta anion gap, } \Delta AG=AG-12
  (\#eq:DelAGap)
\end{equation}

\begin{equation}
  \text{delta bicarbonate, } \Delta HCO_{3}=25-P_{HCO{3}}
  (\#eq:DelHCO)
\end{equation}

\begin{equation}
  \text{delta ratio, } =\frac{\Delta AG}{\Delta HCO_{3}}
  (\#eq:DelRatio)
\end{equation}

\begin{equation}
  \text{delta delta, } \Delta \Delta = \Delta AG - \Delta HCO_{3} \text{ (in ketoacidosis)}\\
  \text{delta delta, } \Delta \Delta = (0.6 \times \Delta AG) - \Delta HCO_{3} \text{ (in lactic acidosis)}\\
  (\#eq:deltadelta)
\end{equation}</div>\EndKnitrBlock{eqnpanel}

The correction factor (0.6) applied when computing the delta in lactic acidosis is thought to be due to lower renal clearance of lactate (compared to ketone) anions [@berend2014].  

Normal range for delta ratio (ΔAG / ΔHCO~3~) is 1 -- 2.  

Therefore to interpret delta ratios:  

![](figures/AG2.png)

`Osmolar gaps` are used to identify exogenous or un-measured osmoles in the plasma (which may be present in a subset of WGMA in which the acid is osmotically active): 

\BeginKnitrBlock{eqnpanel}<div class="eqnpanel">\begin{equation}
  \text{calculated osmolality, } cP_{Osm} =(2\times P_{Na})+P_{urea}+P_{glucose}
  (\#eq:calcOsm)
\end{equation}

\begin{equation}
  \text{osmolar gap, } OG = \text{measured } P_{Osm} - cP_{Osm}
  (\#eq:Osmgap)
\end{equation}</div>\EndKnitrBlock{eqnpanel}

Historically, it has been technically difficult to measure urinary ammonium.  Therefore the *urinary* anion gap has been used as a proxy measure - either in isolation or in combination with the urinary osmolar gap [@kraut2012; @sharma2015]: 

\BeginKnitrBlock{eqnpanel}<div class="eqnpanel">\begin{equation}
  \text{urinary anion gap, } UAG=U_{Na}+U_{K}-U_{Cl}
  (\#eq:urineAGap)
\end{equation}

\begin{equation}
  \text{calculated urinary osmolality, } cU_{Osm} = 2 \times (U_{Na}+U_{K})+U_{urea}+U_{glucose}
  (\#eq:calcUOsm)
\end{equation}

\begin{equation}
  \text{urinary osmolar gap, } UOG=\text{measured } U_{Osm} - cU_{Osm}
  (\#eq:UOsGap)
\end{equation}

\begin{equation}
  \text{urinary cations, } U_{cations}=\frac{U_{Osm}-U_{urea}-U_{glucose}}{2}
  (\#eq:UCat)
\end{equation}

\begin{equation}
  \text{calculated urinary ammonium, } cU_{NH_{4}}\approx UAG \approx \frac{UOG}{2} \approx U_{cations}-(U_{Na}+U_{K})
  (\#eq:UCalcNH)
\end{equation}</div>\EndKnitrBlock{eqnpanel}

UAG normal range is positive 30 -- 50.  

### Causes of a metabolic acidosis

#### Approach to metabolic acidosis


\BeginKnitrBlock{algpanel}<div class="algpanel">Order of investigations in metabolic acidosis:  

1)  cAG -- is this a normal or wide gap acidosis?
2)  ΔAG vs ΔHCO~3~ in WGMA -- is rise in AG proportional to fall in HCO~3~ (or is this a mixed metabolic disorder)?  
3)  PaCO~2~ -- is the fall in PaCO~2~ proportional to the fall in HCO~3~ (0.16 kPa per mM)?  
4)  +/- OG for a WGMA  
5)  +/- UAG for HCMA  
6)  +/- FEHCO~3~ for HCMA with --ve UAG  

ΔAG / ΔHCO~3~ \< 1 mixed WGMA / HCMA or urinary ketone losses (DKA)
ΔAG / ΔHCO~3~ \> 2 mixed WGMA and metabolic alkalosis
  </div>\EndKnitrBlock{algpanel}



#### WGMA

Differential diagnosis of a wide-gap metabolic acidosis:  

<!-- +  **G** \* glycols *ethylene glycol; propylene glycol* -->
<!-- +  **O** oxoproline -->
<!-- +  **L** L-lactate *shock, liver disease, metformin, linezolid (several weeks into Rx)* -->
<!-- +  **D** D-lactate *short bowel syndromes* -->
<!-- +  **M** \* methanol -->
<!-- +  **A** aspirin -->
<!-- +  **R** renal failure -->
<!-- +  **K** \*^?^ ketoacidosis -->

<table>
<tbody>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> G </td>
   <td style="text-align:left;"> glycols ethylene glycol; propylene glycol * </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> O </td>
   <td style="text-align:left;"> oxoproline </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> L </td>
   <td style="text-align:left;"> L-lactate shock, liver disease, metformin, linezolid (several weeks into Rx) </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> D </td>
   <td style="text-align:left;"> D-lactate short bowel syndromes </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> M </td>
   <td style="text-align:left;"> methanol * </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> A </td>
   <td style="text-align:left;"> aspirin </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> R </td>
   <td style="text-align:left;"> renal failure </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> K </td>
   <td style="text-align:left;"> ketoacidosis *(?) </td>
  </tr>
</tbody>
</table>

Propylene glycol (a solvent for parenteral medications: lorazepam, diazepam, phenobarbital) is metabolised to L- and D-lactate.

\* WGMA with elevated OG = EtOH ketoacidosis, MeOH and the glycols. The OG is NOT elevated with salicylates. There is a time-dependant conversion from OG to AG following ingestion of toxic alcohol (metabolites are charged and bind to Na). 

NB Ethylene glycol = high lactate (false +ve) on ABG machine but not formal lab assay.  

<!-- Administer fomepizole early (before significant acidosis). Indications for RRT (prefer HD to HF): acidosis, renal failure, EG level \> 50 mg/L. -->


#### HCMA (normal gap) {#HCMA}

The approach to HCMA has been extensively reviewed [@rodriguezsoriano2002; @kraut2012; @haque2012; @sharma2015).  

The causes can be classified using the urinary anion gap \@ref(eq:urineAGap) and the fractional excretion of bicarbonate \@ref(eq:FEHCO3):  

<!-- +  \+ ve U AG (unable to acidify urine) -->
<!--     +  *RTA type I (always)* -->
<!--     +  *RTA type IV (always)* -->
<!--     +  *RTA type II (sometimes) \** -->

<!-- +  -- ve U AG (able to acidify urine)   -->
<!--     +  renal (FEHCO~3~ \> 10 -- 15 %) -->
<!--         +  *RTA type II (sometimes) \** -->
<!--         +  *RTA of renal insufficiency (GFR \> 15)* -->

<!--     +  extrarenal (FEHCO~3~ \<\< 5 % \*\*)   -->
<!--         +  *diarrhoea (GI HCO~3~ loss)* -->
<!--         +  *ureteric diversion* -->
<!--         +  *pancreatic secretions* -->
<!--         +  *biliary secretions* -->

<table>
<tbody>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> POS U AG (UNABLE TO ACIDIFY URINE) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> RTA </td>
   <td style="text-align:left;"> RTA type I (always) </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> POS U AG (UNABLE TO ACIDIFY URINE) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> RTA </td>
   <td style="text-align:left;"> RTA type IV (always) </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> POS U AG (UNABLE TO ACIDIFY URINE) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> RTA </td>
   <td style="text-align:left;"> RTA type II (sometimes) * </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> NEG U AG (ABLE TO ACIDIFY URINE) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> renal (FEHCO3 &gt; 10 – 15 %) </td>
   <td style="text-align:left;"> RTA type II (sometimes) * </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> NEG U AG (ABLE TO ACIDIFY URINE) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> renal (FEHCO3 &gt; 10 – 15 %) </td>
   <td style="text-align:left;"> RTA of renal insufficiency (GFR &gt; 15) </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> NEG U AG (ABLE TO ACIDIFY URINE) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> extrarenal (FEHCO3 &lt;&lt; 5 % **) </td>
   <td style="text-align:left;"> diarrhoea (GI HCO3 loss) </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> NEG U AG (ABLE TO ACIDIFY URINE) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> extrarenal (FEHCO3 &lt;&lt; 5 % **) </td>
   <td style="text-align:left;"> ureteric diversion </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> NEG U AG (ABLE TO ACIDIFY URINE) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> extrarenal (FEHCO3 &lt;&lt; 5 % **) </td>
   <td style="text-align:left;"> pancreatic secretions </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> NEG U AG (ABLE TO ACIDIFY URINE) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> extrarenal (FEHCO3 &lt;&lt; 5 % **) </td>
   <td style="text-align:left;"> biliary secretions </td>
  </tr>
</tbody>
</table>

\* The UAG is positive in all distal RTA. It may be positive or negative in proximal RTA.

\*\* FEHCO~3~ also \< 5 % in dRTA.

\BeginKnitrBlock{eqnpanel}<div class="eqnpanel">\begin{equation}
  FE_{HCO_{3}} = \frac{U_{HCO_{3}}}{P_{HCO_{3}}} \times \frac{P_{Creat}}{U_{Creat}}
  (\#eq:FEHCO3)
\end{equation}
    </div>\EndKnitrBlock{eqnpanel}

Hyperchloraemic acidosis may also be caused by iatrogenic `chloride excess`.  This may be particularly pronounced when IV NaCl is used to replace losses of urinary anions that represent a store of "potential bicarbonate" - e.g. ketone bodies or D-lactate [@sabatini2009].

Historically, TPN was a cause of "hyperalimentation acidosis" (as cationic amino acids were metabolised to sulphuric acid) - but contemporary formulations contain a source of potential bicarbonate (e.g. acetate) to offset this.  

### Cautions in the interpretation of UAG

i) extreme volume depletion 
    - results in low UNa and UCl
    - low UCl limits NH~4~ excretion and may therefore lead to a "spurious" positive UAG in diarrhoea  

ii) ketoacidosis 
    - unmeasured anions in the urine (β-hydroxybutyrate and acetoacetone)
    - may therefore lead to a positive UAG even though urinary NH4+ excretion is increased\...
    - ...detect this by measuring the urinary osmolar gap  

iii) glue-sniffing (toluene) 
    - unmeasured anions in the urine (hippurate) 

A +ve UAG in the context of *alkaline* urine could signify bicarbonaturia (post-vomiting, loop diuretics, post-hypercapnoea).


## Renal tubular acidosis

Free [H^+^] is nM, but we need to excrete mmoles (1 mmol / kg on Western diet), therefore must be buffered by NH~4~, PO~4~...

### Classification of RTA  

+  type II (pRTA) *impaired reabsorption of HCO3*  


+  type I (dRTA) *inability to secrete acid* 
    +  *complete dRTA systemic acidosis (impaired ammoniagenesis)* 
    +  *partial dRTA no acidosis (preserved ammoniagenesis)*  

    
+  type IV *impaired ammoniagenesis (due to hyperK); deficient aldosterone or CD abnormality*  


+  type III (mixed) *CA inhibition*  


+  RTA in CKD *HCMA when GFR \< 30; WGMA when GFR \< 15*  

### Associations

- dRTA CaP stones (alkaline urine, hypocitraturia)  
- nephrocalcinosis (in inherited but NOT acquired forms)  
- osteoporosis  

### Investigation of suspected RTA

+  UAG & FENaHCO~3~  
+  urine pH (never \< 5.5 in dRTA)  
+  in suspected pRTA 
    +  *tubular reabsorption of phosphate (TRP = 100 - FEPO~4~) \< 85 %* 
    +  *glycosuria, aminoaciduria, LMW proteinuria*  
+  in suspected dRTA 
    +  *furosemide-fludrocortisone (FF) test (failure to achieve pH \< 5.3 , 3 -- 4 hrs after 40 -- 80 mg / 1 mg)* 
    +  *UCa \> 4 mg / kg / day (or spot UCa/Cr \> 0.2) in type I RTA* 
    +  *USS / KUB (medullary nephrocalcinosis in type I RTA)* 
    +  *urinary citrate (low in type I RTA; high in type II / IV RTA)*  

### Causes

<!-- +  pRTA (isolated)  -->
<!--     +  inherited  -->
<!--     +  acquired *topiramate*   -->


<!-- +  pRTA (with Fanconi)  -->
<!--     +  inherited *NBCe1A (AR with ocular abnormalities)*  -->
<!--     +  metabolic *Wilson's, cystinosis, fructose intolerance, Dent's, mitochondrial cytopathies*  -->
<!--     +  dysproteinaemia *myeloma, LCDD, LCFS is κ in 96 %, amyloid*  -->
<!--     +  tubulointerstitial *interstitial nephritis (inc. Sjogren's), allograft rejection*  -->
<!--     +  drugs *(Abx / cART)* *tenofovir, lamivudine, aminoglycosides, outdated tetracyclines*  -->
<!--     +  drugs *(other) cisplatin, valproate, lenalinomide*  -->
<!--     +  toxins *Pb, Hg, Cd, aristolochic acid*   -->


<!-- +  dRTA  -->
<!--     +  inherited *AEI (AR), H-ATPase B1 (AR with SNHL), H-ATPase A4 (AR)*  -->
<!--     +  tubulointerstitial *chronic pyelonephritis, chronic TIN, obstructive uropathy, sickle cell, rejection*  -->
<!--     +  autoimmune *hypergammaglobulinaemia, SLE, Sjogren's, chronic active hepatitis, PBC*  -->
<!--     +  drugs *Li^+^, amphoterecin, toluene*  -->
<!--     +  nephrocalcinosis *hyperPTH, idiopathic hypercalciuria, MSK*   -->


<!-- +  type IV  -->
<!--     +  low renin *DM, NSAIDs, CNIs, β--*  -->
<!--     +  high renin *Addisons, CAH, ACEi, ARB, heparin, ketoconazole*  -->
<!--     +  abnormal CD *TIN, spiro, amiloride, trimethoprim*   -->


<!-- +  type III  -->
<!--     +  inherited *CAII (AR with osteopetrosis / cerebral calcification)*  -->
<!--     +  acquired *topiramate (CA inhibition)*   -->

<table>
<tbody>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> PRTA (ISOLATED) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> inherited </td>
   <td style="text-align:left;"> inherited </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> PRTA (ISOLATED) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> acquired </td>
   <td style="text-align:left;"> topiramate </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> PRTA (WITH FANCONI) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> inherited </td>
   <td style="text-align:left;"> NBCe1A (AR with ocular abnormalities) </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> PRTA (WITH FANCONI) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> metabolic </td>
   <td style="text-align:left;"> Wilson's </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> PRTA (WITH FANCONI) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> metabolic </td>
   <td style="text-align:left;"> cystinosis </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> PRTA (WITH FANCONI) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> metabolic </td>
   <td style="text-align:left;"> fructose intolerance </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> PRTA (WITH FANCONI) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> metabolic </td>
   <td style="text-align:left;"> Dent disease </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> PRTA (WITH FANCONI) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> metabolic </td>
   <td style="text-align:left;"> mitochondrial cytopathies </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> PRTA (WITH FANCONI) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> dysproteinaemia </td>
   <td style="text-align:left;"> myeloma </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> PRTA (WITH FANCONI) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> dysproteinaemia </td>
   <td style="text-align:left;"> LCDD </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> PRTA (WITH FANCONI) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> dysproteinaemia </td>
   <td style="text-align:left;"> LCFS is κ in 96 %, </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> PRTA (WITH FANCONI) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> dysproteinaemia </td>
   <td style="text-align:left;"> amyloid </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> PRTA (WITH FANCONI) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> TIN </td>
   <td style="text-align:left;"> Sjogren's </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> PRTA (WITH FANCONI) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> TIN </td>
   <td style="text-align:left;"> other TIN </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> PRTA (WITH FANCONI) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> TIN </td>
   <td style="text-align:left;"> allograft rejection </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> PRTA (WITH FANCONI) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> drugs (Abx / cART) </td>
   <td style="text-align:left;"> tenofovir </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> PRTA (WITH FANCONI) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> drugs (Abx / cART) </td>
   <td style="text-align:left;"> lamivudine </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> PRTA (WITH FANCONI) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> drugs (Abx / cART) </td>
   <td style="text-align:left;"> aminoglycosides </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> PRTA (WITH FANCONI) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> drugs (Abx / cART) </td>
   <td style="text-align:left;"> outdated tetracyclines </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> PRTA (WITH FANCONI) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> drugs (other) </td>
   <td style="text-align:left;"> cisplatin </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> PRTA (WITH FANCONI) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> drugs (other) </td>
   <td style="text-align:left;"> valproate </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> PRTA (WITH FANCONI) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> drugs (other) </td>
   <td style="text-align:left;"> lenalinomide </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> PRTA (WITH FANCONI) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> toxins </td>
   <td style="text-align:left;"> Pb </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> PRTA (WITH FANCONI) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> toxins </td>
   <td style="text-align:left;"> Hg </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> PRTA (WITH FANCONI) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> toxins </td>
   <td style="text-align:left;"> Cd </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> PRTA (WITH FANCONI) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> toxins </td>
   <td style="text-align:left;"> aristolochic acid </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> DRTA </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> inherited </td>
   <td style="text-align:left;"> AEI (AR) </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> DRTA </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> inherited </td>
   <td style="text-align:left;"> H-ATPase B1 (AR with SNHL) </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> DRTA </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> inherited </td>
   <td style="text-align:left;"> H-ATPase A4 (AR) </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> DRTA </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> TIN </td>
   <td style="text-align:left;"> chronic pyelonephritis </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> DRTA </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> TIN </td>
   <td style="text-align:left;"> chronic TIN </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> DRTA </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> TIN </td>
   <td style="text-align:left;"> obstructive uropathy </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> DRTA </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> TIN </td>
   <td style="text-align:left;"> sickle cell </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> DRTA </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> TIN </td>
   <td style="text-align:left;"> allograft rejection </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> DRTA </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> autoimmune </td>
   <td style="text-align:left;"> hypergammaglobulinaemia </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> DRTA </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> autoimmune </td>
   <td style="text-align:left;"> SLE </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> DRTA </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> autoimmune </td>
   <td style="text-align:left;"> Sjogren's </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> DRTA </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> autoimmune </td>
   <td style="text-align:left;"> chronic active hepatitis </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> DRTA </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> autoimmune </td>
   <td style="text-align:left;"> PBC </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> DRTA </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> drugs </td>
   <td style="text-align:left;"> Li+ </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> DRTA </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> drugs </td>
   <td style="text-align:left;"> amphoterocin </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> DRTA </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> drugs </td>
   <td style="text-align:left;"> toluene </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> DRTA </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> nephrocalcinosis </td>
   <td style="text-align:left;"> hyperPTH </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> DRTA </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> nephrocalcinosis </td>
   <td style="text-align:left;"> idiopathic hypercalciuria </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> DRTA </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> nephrocalcinosis </td>
   <td style="text-align:left;"> MSK </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> TYPE IV </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> low renin </td>
   <td style="text-align:left;"> DM </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> TYPE IV </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> low renin </td>
   <td style="text-align:left;"> NSAIDs </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> TYPE IV </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> low renin </td>
   <td style="text-align:left;"> CNIs </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> TYPE IV </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> low renin </td>
   <td style="text-align:left;"> β– </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> TYPE IV </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> high renin </td>
   <td style="text-align:left;"> Addison's </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> TYPE IV </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> high renin </td>
   <td style="text-align:left;"> CAH </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> TYPE IV </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> high renin </td>
   <td style="text-align:left;"> ACEi / ARB </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> TYPE IV </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> high renin </td>
   <td style="text-align:left;"> heparin </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> TYPE IV </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> high renin </td>
   <td style="text-align:left;"> ketoconazole </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> TYPE IV </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> abnormal CD </td>
   <td style="text-align:left;"> TIN </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> TYPE IV </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> abnormal CD </td>
   <td style="text-align:left;"> sprionolactone / amiloride </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> TYPE IV </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> abnormal CD </td>
   <td style="text-align:left;"> trimethoprim </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> TYPE III </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> inherited </td>
   <td style="text-align:left;"> CAII (AR with osteopetrosis / cerebral calcification) </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;"> TYPE III </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> acquired </td>
   <td style="text-align:left;"> topiramate (CA inhibition) </td>
  </tr>
</tbody>
</table>

Sjogrens classically causes a dRTA (but can also cause pRTA if interstitial nephritis).

Mitochondrial cytopathy: raised CK, abnormal number of microchondria (EM).

<!-- ### Treatment -->

<!-- +  K citrate  -->
<!-- +  +/- NaHCO~3~  -->
